Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.26 USD
Change Today +0.11 / 3.49%
Volume 1.3M
XOMA On Other Exchanges
Symbol
Exchange
Frankfurt
As of 12:37 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

xoma corp (XOMA) Snapshot

Open
$3.23
Previous Close
$3.15
Day High
$3.32
Day Low
$3.20
52 Week High
11/28/14 - $5.95
52 Week Low
04/30/15 - $2.92
Market Cap
381.2M
Average Volume 10 Days
2.2M
EPS TTM
$-0.36
Shares Outstanding
116.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for XOMA CORP (XOMA)

xoma corp (XOMA) Related Bloomberg News

View More Bloomberg News

xoma corp (XOMA) Related Businessweek News

No Related Businessweek News Found

xoma corp (XOMA) Details

XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company’s lead product candidate includes gevokizumab, a proprietary humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III clinical trial for NIU and Behçet’s disease uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, autoimmune inner ear disease, and cardiovascular diseases, as well as diseases under the neutrophilic dermatoses designation, Schnitzler syndrome, and other diseases; and various proof-of-concept studies comprising polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis. Its proprietary product pipeline also comprises XOMA metabolic activating, sensitizing, and deactivating/antagonizing antibodies that are in preclinical stage for the treatment of diabetes patients; XOMA 3AB, a multi-antibody product for the treatment of human botulism poisoning; and XOMA 629, a topical anti-bacterial product for the treatment of human immune system. In addition, the company licenses antibody discovery, optimization, and development technologies, including Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX. It has collaboration and licensing agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Novartis AG; Pfizer Inc.; Symplmed Pharmaceuticals, LLC; and Texas A&M University. The company was founded in 1981 and is headquartered in Berkeley, California.

183 Employees
Last Reported Date: 03/11/15
Founded in 1981

xoma corp (XOMA) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $569.5K
Founder, Chief Scientific Officer, Executive ...
Total Annual Compensation: $250.3K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $411.0K
Chief Commercial Officer and Vice President
Total Annual Compensation: $391.4K
Compensation as of Fiscal Year 2014.

xoma corp (XOMA) Key Developments

XOMA Corporation Presents at Credit Suisse 2015 Antibody Day, May-06-2015 08:35 AM

XOMA Corporation Presents at Credit Suisse 2015 Antibody Day, May-06-2015 08:35 AM. Venue: Credit Suisse, One Madison Avenue at 24th Street, 12th Floor, New York, New York, United States. Speakers: Paul D. Rubin, Chief Medical Officer and Senior Vice President of Research & Development.

XOMA Corporation Initiates Phase 2 Study of Gevokizumab in Patients with Diabetic Nephropathy

XOMA Corporation announced gevokizumab will be tested in a Phase 2 study in patients with Type 2 diabetes and diabetic kidney disease, clinically referred to as diabetic nephropathy. The international, multicenter, randomized, double-blind, parallel-group, placebo-controlled study is expected to enroll 370 patients who will be randomized to receive gevokizumab or placebo for 52 weeks. The primary objective of this study is to detect the existence of an overall dose-response relationship of subcutaneously dosed gevokizumab on the measured glomerular filtration rate (mGFR), an accurate measure of kidney function, at Week 52. The study also will determine gevokizumab's effect on a number of biological biomarkers assessing kidney function. Servier will fully sponsor the study's execution and cost.

XOMA Corporation Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Cash Flow Guidance for 2015

XOMA Corporation reported consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company recorded revenues of $4.3 million compared with $12.5 million in the corresponding 2013 period. For the quarter ended December 31, 2014, the company reported net loss of $7.3 million, which included a gain of $12.1 million directly related to the revaluation of contingent warrant liabilities. Excluding the noncash revaluation of contingent warrant liabilities, net loss for the 2014 fourth quarter was $19.4 million. For the quarter ended December 31, 2013, the company reported net loss of $52.3 million, of which $35.3 million was directly related to the revaluation of contingent warrant liabilities. Excluding the noncash revaluation of contingent warrant liabilities, net loss for the quarter ended December 31, 2013, was $17 million. So without the warrant liability revaluations, the 2014 net loss was $19.4 million compared to $17 million in 2013. Loss from operations was $19.127 million against $15.580 million for the same period a year ago. Diluted net loss per share of common stock was $0.12 against $0.55 for the same period a year ago. The company recorded total revenues of $18.9 million for the year ended December 31, 2014. For the year ended December 31, 2013, the company recorded total revenues of $35.5 million. The decrease in the full year and fourth quarter of 2014 revenues were due primarily to reduced revenue from cost during collaboration with Servier and reduced license fee revenue, including the $7 million milestone payment received from Novartis in 2013. For the year ended December 31, 2014, the company had net loss of $38.3 million compared with net loss of $124.1 million in the year ended December 31, 2013. The full year net losses in 2014 and 2013 included a $45.8 million gain and $61 million loss, respectively, in a noncash revaluation of contingent warrant liabilities, which resulted primarily from fluctuations in XOMA's stock price. Excluding those revaluations, net loss for 2014 was $84.1 million and net loss for 2013 was $63 million. Loss from operations was $81.832 million against $58.205 million for the same period a year ago. Diluted net loss per share of common stock was $0.67 against $1.43 for the same period a year ago. The company expects cash used in ongoing operating activities during 2015 will be approximately $60 million to $65 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XOMA:US $3.26 USD +0.11

XOMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
arGEN-X BV €9.40 EUR +0.05
BioInvent International AB kr1.88 SEK -0.03
Intrexon Corp $39.57 USD +0.48
MorphoSys AG €62.39 EUR -1.61
PDL BioPharma Inc $6.48 USD -0.025
View Industry Companies
 

Industry Analysis

XOMA

Industry Average

Valuation XOMA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.8x
Price/Book 121.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XOMA CORP, please visit www.xoma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.